Search our science

Davis JA, de Moerloose P, Benchikh El Fegoun S, Habis R, Klamroth R. A survey among patients with hemophilia and inhibitors seeking treatment in non-hemophilia treatment centers . National Hemophilia Foundation - 71st Annual Meeting. 2019.

Rajpurkar M, Croteau S, Boggio L, Copper D. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019;10:335-340.

Buckner T, Sidonio R, Witkop M, Guelcher C, Cutter S, Iyer N, Cooper D. Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study. Pat Rel Outcomes Meas. 2019;1-16.

Levy GG, Asikanius E, Kuebler P, Benchikh el Fegoun S, Esberg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-77.

Sun J, Livingston EW, Broberg ML, Johansen PB, Ley CD, Knudsen T, Ezban M, Bateman TA, Monahan PE, Taves S. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding.J Thromb Haemost. 2019;17:1240-1246.

Blamey G, Buranahirum C, Buzzi A, Cooper DL, Cutter S, Geraghty S, Saad H, Yang R. Hemophilia and sexual health: results from the HERO and B-HERO-S studies. Pat Rel Outcomes Meas. 2019;2019:243–255.

Cutter S, Guelcher C, Hunter S, Rotellini D, Dunn S, Cooper D. Mild-Severe Hemophilia B Impacts Relationships for US Adults and Children With Hemophilia B and Their Families: Results From the Bridging Hemophilia B Experiences, Results, and Opportunities Into Solutions (B-HERO-S) Study. Pat Rel Outcomes Meas. 2019;2019:257-266.

Yuan D, Rode F, Cao Y. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. Eur J Pharm Sci. 2019;138:105032.

Escobar M, Walsh C, Cooper D, Young, G. Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data. J Blood Med. 2019;10:243-250.

Tiefenbacher S, Clausen WHO, Hansen M, Lützhøft R, Ezban M. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical hemostasis laboratories. Haemophilia. 2019;1-9.

Chowdary P, Carcao M, Holme P, Jiménez Yuste V, Lentz SR, Moss J, Hvitfeldt Poulsen L, Shen C, Tosetto A, Wheeler A, Santagostino E. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. Res Pract Thromb Haemost. 2019;3(3):542-554.

Curry NJ, Chowdary P, Geybels M, Landorph A, Lentz SR, Meunier S, Oldenburg J, Rageliene L, Santagostino E. Long-term safety of N8-GP (turoctocog alfa pegol) prophylaxis in patients with severe haemophilia A. Res Pract Thromb Haemost. 2019;3(Suppl 1):1-891.

de Moerloose P, Davis JA, Benchikh El Fegoun S, Habis R, Klamroth R. Barriers and challenges for the fast treatment of bleeds in the non-haemophilia treatment centre hospital setting. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Astermark J, Angchaisuksiri P, Benson G, Castaman G, Chowdary P, Eichler E, Hvitfeldt-Poulsen L, Jimenez Yuste V, Kavakli K, Matsushita T, Oldenburg J, Paroski-Wheeler A, Shapiro, A, Zupancic-Salek S, Young G. Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in haemophilia A and haemophilia A/B with inhibitors: Phase 2 trial results. International Society on Thrombosis and Haemostasis - 27th Congress. 2019;3(S1).

Astermark J, Angchaisuksiri P, Benson G, Castaman G, Chowdary P, Eichler E, Hvitfeldt-Poulsen L, Jimenez Yuste V, Kavakli K, Matsushita T, Oldenburg J, Paroski-Wheeler A, Shapiro, A, Zupancic-Salek S, Young G. Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in haemophilia A and haemophilia A/B with inhibitors: Phase 2 trial results. International Society on Thrombosis and Haemostasis - 27th Congress. 2019;3(S1).

Enoksson M, Martin EJ, Holmberg H, Jensen MS, Kjeldgaard-Hansen M, Egebjerg T, Buchardt J, Demuth H, Sanfridson A, Hilden I, Kjalke M, Brophy DF. Enhanced potency of recombinant factor VIIa upon targeting to activated platelets. J Thromb Haemost. 2019;18(1):104-113.

Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P. Immunogenicity, safety, pharmacokinetics and preliminary efficacy results from the first human subcutaneous factor VIII trial (subcutaneous turoctocog alfa pegol, SC N8-GP) in previously treated patients with hemophilia A (alleviate 1). ISTH 2019.

Barnes C, Chan KC, Alamelu J, Garly M-L, Meldgaard RM, Young G. First report of an extended half-life FIX in previously untreated patients with haemophilia B. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Barnes C, Chan A, Alamelu J, Garly M-L, Meldgaard RM, Young G. First report of an extended half-life FIX in previously untreated patients with haemophilia B. Res Pract Thromb Haemost. 2019;3(Suppl. 1):1-228.

Chowdary P, Chitlur M, Clausen WHO, Escobar M, Kearney S, Landorph A, Hvitfeldt Poulsen L, Santagostino E. N8-GP treatment sustains low bleeding rates in patients with severe haemophilia A. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d’Oiron R, Benchikh El Fegoun S, Kessler C. Delphi expert consensus statements on clinical evaluation of bleeds in patients with acquired haemophilia. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Carcao M, Kearney S, Taki M, Rubens D, Pietzko K, Santagostino E. Nonacog beta pegol administered for at least 5 years shows long-term safety and efficacy in previously treated children with haemophilia B. International Society on Thrombosis and Haemostasis - 27th Congress. 2019.

Sun J, Xu W, Wu R, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Korsholm L, Matytsina I, Zhang S, Yang R. Successful haemostatic response and effective prophylaxis with turoctocog alfa in previously treated patients from China with severe haemophilia A (guardian 7). Research and Practice in Thrombosis and Haemostasis. 2019;3(Suppl. 1):265.

Gupta N, Benbouzid A, Belhani M, El Andaloussi M, Maani K, Wali Y, Benchikh El Fegoun S, Ali Saad H, Mahlangu J. HAEMOcare: The first international epidemiological study measuring burden of hemophilia in developing countries. TH Open. 2019;03(02):e190-e199.

Tiede A,Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d’Oiron R, Benchikh El Fegoun S, Kessler C. Delphi expert consensus statements on clinical evaluation of bleeds in patients with acquired haemophilia. Res Pract Thromb Haemost . 2019;3(Suppl 1):1-891.

Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P. Immunogenicity, safety, pharmacokinetics and preliminary efficacy results from the first human subcutaneous factor VIII trial (subcutaneous turoctocog alfa pegol, SC N8-GP) in previously treated patients with hemophilia A (alleviate 1). Res Pract Thromb Haemost. 2019;3(Suppl. 1):1-228.